+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Vaccine News Moderna S Clinical Trial Numbers Show There S No Way Trump Can Have A Vaccine By Election Day Cnn is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Vaccine News Moderna S Clinical Trial Numbers Show There S No Way Trump Can Have A Vaccine By Election Day Cnn | RobinsPost News & Noticias

Moderna's Next Gen COVID Vaccine Meets Primary Goal In Late-Stage Trial


Moderna announces Phase 3 trial results for mRNA-1283, its next-gen COVID-19 vaccine. A higher immune response was observed compared to mRNA-1273.222. Detailed data will be unveiled at upcoming events ... Read More

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine


Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company’s next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a ... Read More

What's Going On With Moderna Stock Wednesday?


Moderna shares are trading higher Wednesday after the company announced that MRNA-1283 met the primary endpoints in its Phase 3 clinical trial. Additionally, Blackstone Life Sciences announced an ... Read More

Moderna's MRNA-1283 COVID-19 Vaccine Design Meets Primary Endpoints In Phase 3 Clinical Trial


Moderna, Inc. (MRNA) announced on Tuesday that its next-generation COVID-19 vaccine design mRNA-1283 has met the primary endpoints of ... Read More

Moderna’s Promising Vaccine Pipeline Balanced with Near-Term Caution: Hold Rating Maintained


The company’s Annual Vaccines Day showcased ... which may have influenced Stringer’s decision to maintain a Hold rating. It seems that while there is recognition of Moderna’s significant opportunities ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus